Survival of AIDS patients and characteristics of those who died over eight years of highly active antiretroviral therapy, at a referral center in Northeast Brazil

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 4, 2008, Pages 269-277

  Santos Wolmer de Melo, Ladjane ^a   Lacerda, Heloisa Ramos ^a   Campelo, Eduardo ^a   Moraes, Emanuel ^a   de Alencar Ximenes, Ricardo Arraes ^a,b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b Federal University of Pernambuco ^*  (Brazil)

Author keywords

AIDS; Brazil; Cause of death; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; HEMOGLOBIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BRAZIL; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DISEASE DURATION; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT MONITORING; RESPIRATORY TRACT INFECTION; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SEXUAL BEHAVIOR; SURVIVAL RATE; SURVIVAL TIME;

EID: 60649119649     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702008000400003     Document Type: Article

References (39)

1. Palella F.J. Jr., Delaney K.N., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Marins J.R., Jamal L.F., Chen S.Y., et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003; 17:1675-82.
3. Gianna M.C., Kalichman A. Editorial. JBA 2006;7:1.
4. Lieb S., Brooks R.G., Hopkins R.S., et al. Predicting death from HIV/ AIDS: a case-control study from Florida public HIV/AIDS clinics. J Acquir Immune Defic Syndr 2002;30:351-8.
5. Teodor A., Teodor D., Luca V. Side effects of antiretroviral therapy. Rev Med Chir Soc Med Nat Iasi 2004;108:23-6.
6. Saraceni V., Da Cruz M.M., Lauria L. de M., Durovin B. Trends and characteristics of AIDS mortality in Rio de Janeiro city after introduction of highly antiretroviral therapy. The Braz J Infect Dis 2005;9:209-15.
7. Valdez H., Chowdhry T.K., Asaad R., et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001;32:1487-93.
8. a semanas epidemiológicas - janeiro a julho de 2007.
9. Kleinbaum D.G. Survival Analysis: a self-learning text. (Statistics in the health sciences). New York: Springer-Verlag: 1995.
10. Signorini D.J.H.P., Codeço C.T., Carvalho M.S., et al. Effect of sociodemographic and therapeutic procedures on survival of AIDS patients assisted in Brazilian outpatient clinic. Rev Bras Epidemiol 2005; 8:253-61.
11. Fang C.T., Chang H.M., Hsu H.M., et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM. 2007;100:97-105.
12. State Health Department - Pernambuco. Boletim Informativo DST/AIDS, ano VI, n. 2, set 2006.
13. Casseb J., Fonseca L.A., Veiga A.P., et al. AIDS incidence and mortality in a hospital-based cohort of HIV-1-seropositive patients receiving highly active antiretroviral therapy in São Paulo, Brazil. AIDS Patients Care STDS 2003;17:447-52.
14. Bruun J.N., Skeie L., Maeland A., et al. HIV/AIDS - From lethal syndrome to chronic disease. Tidsskr Nor Laegeforen 2006;126:3121-4.
15. Zhou J., Kumarasamy N., TREAT Asia HIV Observational Database. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the treatment. Asia HIV observational database (TAHOD). HIV Medicine 2005; 6:216-23.
16. O'Brien M.E., Kupqa R., Msamanga G.I., et al. Anemia is an independent predictor of mortality and immunologic progression of disease among women with HIV in Tanzania. J Acquir Immune Defic Syndr 2005; 40:219-25.
17. Mocroft A., Ledergerber B., Katlama C., et al. Decline in the AIDS and death rates in the Euro SIDA study: an observational study. Lancet 2003;362:22-9.
18. Acurcio F.A., Cesar C.C., Guimarães M.D. Health care utilization and survival among patients with AIDS in Belo Horizonte, Minas Gerais, Brazil. Cad Saude Publica 1998;14:811-20.
19. Braga P., Cardoso M.R., Segurado A.C. Gender differences in survival in an HIV/AIDS cohort from São Paulo, Brazil. AIDS Patient Care STDS 2007;21:321-8.
20. Krentz H.B., Kliewer G., Gill M.J. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005;6:99-106.
21. Reif S., Golin C.E., Smith S.R. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences. AIDS Care 2005; 17:558-65.
22. dos Santos M.A., Albuquerque M.F., Ximenes R.A., et al. Risk factors for treatment delay in pulmonary tuberculosis in Recife, Brazil. BMC Public Health 2005;5:25.
23. Mandell D. Principles & Practice of Infectious Diseases 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005.
24. Medeiros L.B., Lacerda H.R., Cavalcanti A.M., Albuquerque M. de F. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz 2006; 101:845-9.
25. Mills E.J., Nachega J.B., Bangsberg D.R., et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006;3:e438.
26. Lu T.H., Chang H.J., Chen L.S., et al. Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan. J Formos Med Assoc 2006;105:604-9.
27. Casalino E., Wolff M., Ravaud P., et al. Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004;18:1429-33.
28. Palella F.R. Jr., Baker R.K., Moorman A.C., et al. Mortality in highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
29. Mocroft A., Brettle R., Kirk O., et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002;16:1663-71.
30. Cowan M.J., Shelahmer J.H., Levine S.J. Acute respiratory failure in the HIV-seropositive patient. Crit Care Clin 1997;13:523-52.
31. Moroni M., Franzetti F. Bacterial pneumonia in adult patients with HIV infection. J Chemother 1995;7:292-306.
32. Wolff A.J., O'Donnell A.E. Pulmonary manifestation of HIV infection in the era of highly active antiretriviral therapy. Chest 2001; 120:1888-93.
33. De Backer A.I., Mortele K.J., De Keulenaer B.L., Parizel P.M. Tuberculosis: epidemiology, manifestations and the value of medical imaging in diagnosis. JBR-BTR 2006;89:243-50.
34. Da Silva R.M., Teixeira P.J., Moreira J. da S. The clinical utility of induced sputum for diagnosis of bacterial community-acquired pneumonia in HIV-infected patients: a prospective cross-sectional study. Braz J Infect Dis 2006;10:89-93.
35. Blum T., Roth A., Mauch H., et al. Pneumocystis jiroveci pneumonia in immunocompromised patients without AIDS - a case series. Dtsch Med Wochenschr 2006;131:1515-20.
36. Waite S., Jeudy J., White C.S. Acute lung infections in normal and immunocompromised hosts. Radiol Clin North Am 2006;44:295-315.
37. Rosenberg A.L., Seneff M.G., Atiyeh L., et al. The importance of bacterial sepsis in intensive care unit patients with acquired immunodeficiency syndrome: implications for future care in the age of increasing antiretroviral resistance. Crit Care Med 2001; 29:548-56.
38. Huang L., Hecht F.M., Stansell J.D., et al. Suspected Pneumocystis carinii with a negative induced sputum examination. Is early bronchoscopy useful? Am J Respir Crit Care Med 1995;151:1866-71.
39. Gracia J.D., Miravitlles M., Mavordomo C., et al. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Chest 1997;111:1180-6.